Alta Life Sciences has led a series-A round of funding for Peptomyc, which has secured €4.2 million. This was the first investment by the new life sciences fund led by Guy Paul Nohra in Barcelona, with partner Montserrat Vendrell (we recommend the video-interview from CataloniaBio) representing the fund on the Peptomyc board.

Healthequity and several business angels, previous investors in Peptomyc, also participated in this round of funding. Law firm RCD advised on the transaction.

Peptomyc is a biopharmaceutical company based in Barcelona that was founded by scientists Laura Soucek and Marie-Eve Beaulieu of the Vall d'Hebron Institute of Oncology (watch the video-interview by CataloniaBio) that is developing new peptide-based therapies to treat cancer. This investment will give them the capital they need to made significant advances in producing their peptides according to CMC standards (Chemical Manufacturing Control) and conducting non-clinical studies to demonstrate their safety and efficacy, taking the company ever closer to starting clinical trials.

Alta Life Sciences, Peptomyc, Healthequity and RCD are CataloniaBio members.

More information is available on the Alta Life Sciences and Peptomyc websites.

Photo: Laura Soucek, Montserrat Vendrell and Marie-Eve Beaulieu – © Alta Life Sciences